

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/277079996>

# Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa

ARTICLE in JOURNAL OF NATURAL PRODUCTS · MAY 2015

Impact Factor: 3.8 · DOI: 10.1021/acs.jnatprod.5b00065 · Source: PubMed

---

READS

205

## 11 AUTHORS, INCLUDING:



**Mohamed M Radwan**

University of Mississippi

102 PUBLICATIONS 582 CITATIONS

SEE PROFILE



**Mahmoud A Elsohly**

University of Mississippi

207 PUBLICATIONS 4,011 CITATIONS

SEE PROFILE



**Abir El-Alfy**

Chicago State University

30 PUBLICATIONS 549 CITATIONS

SEE PROFILE



**Samir A Ross**

University of Mississippi

214 PUBLICATIONS 2,340 CITATIONS


SEE PROFILE

# Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency *Cannabis sativa*

Mohamed M. Radwan,<sup>†</sup> Mahmoud A. ElSohly,<sup>\*,†,‡</sup> Abir T. El-Alfy,<sup>§,⊥</sup> Safwat A. Ahmed,<sup>†,||</sup> Desmond Slade,<sup>†</sup> Afeef S. Husni,<sup>§</sup> Susan P. Manly,<sup>§</sup> Lisa Wilson,<sup>§</sup> Suzanne Seale,<sup>§</sup> Stephen J. Cutler,<sup>†,§</sup> and Samir A. Ross<sup>\*,†,§</sup>

<sup>†</sup>National Center for Natural Products Research, <sup>‡</sup>Department of Pharmaceutics and Drug Delivery, and <sup>§</sup>Department of BioMolecular Sciences, School of Pharmacy, The University of Mississippi, University, Mississippi 38677, United States

## Supporting Information



**ABSTRACT:** Seven new naturally occurring hydroxylated cannabinoids (1–7), along with the known cannabiripsol (8), have been isolated from the aerial parts of high-potency *Cannabis sativa*. The structures of the new compounds were determined by 1D and 2D NMR spectroscopic analysis, GC-MS, and HRESIMS as 8 $\alpha$ -hydroxy- $\Delta^9$ -tetrahydrocannabinol (1), 8 $\beta$ -hydroxy- $\Delta^9$ -tetrahydrocannabinol (2), 10 $\alpha$ -hydroxy- $\Delta^8$ -tetrahydrocannabinol (3), 10 $\beta$ -hydroxy- $\Delta^8$ -tetrahydrocannabinol (4), 10 $\alpha$ -hydroxy- $\Delta^9$ ,11-hexahydrocannabinol (5), 9 $\beta$ ,10 $\beta$ -epoxyhexahydrocannabinol (6), and 11-acetoxy- $\Delta^9$ -tetrahydrocannabinolic acid A (7). The binding affinity of isolated compounds 1–8,  $\Delta^9$ -tetrahydrocannabinol, and  $\Delta^8$ -tetrahydrocannabinol toward CB1 and CB2 receptors as well as their behavioral effects in a mouse tetrad assay were studied. The results indicated that compound 3, with the highest affinity to the CB1 receptors, exerted the most potent cannabimimetic-like actions in the tetrad assay, while compound 4 showed partial cannabimimetic actions. Compound 2, on the other hand, displayed a dose-dependent hypolocomotive effect only.


Many natural product classes besides the cannabinoids have been identified from *Cannabis sativa* L. (Cannabaceae), including monoterpenes, sesquiterpenes, flavonoids, steroids, and nitrogenous compounds. However, the C<sub>21</sub> terpenophenolics (cannabinoids) are characteristic structures found in *C. sativa*. To date, more than 750 constituents have been identified from cannabis, out of which 104 are classified as cannabinoids.<sup>1–14</sup>

The medicinal properties of cannabis have been much debated from scientific and political points of view, and the subject has gained much interest over the years. After the discovery of the primary active constituent of marijuana, (–)-*trans*- $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC), in 1964,<sup>15</sup> various clinical trials were undertaken to determine its efficacy as an analgesic,<sup>16</sup> antiemetic,<sup>17</sup> antidepressant,<sup>18</sup> and appetite suppressant/stimulant,<sup>19</sup> as a treatment of glaucoma,<sup>20</sup> and for the management of chemotherapy-induced nausea and vomiting.<sup>21</sup> Research in the area of the use of *C. sativa* for medicinal purposes has gained worldwide interest following the discovery of the endogenous endocannabinoid system that interacts with the constituents of this plant.

Features of this endogenous system include cannabinoid receptors, of which there are two types reported (CB1 and CB2), and endogenous ligands that act as receptor agonists and antagonists.<sup>22,23</sup> The CB1 receptors, recognized by the cannabinoids, are found in the brain and peripheral tissue of the central nervous system (CNS),<sup>24</sup> while CB2 receptors are found primarily outside the CNS in tissues associated with the immune system of the body.<sup>25</sup>

The availability of high-potency marijuana with unprecedented  $\Delta^9$ -THC concentrations (>20% by dry weight)<sup>26</sup> has afforded an opportunity to discover novel constituents from *C. sativa*. As part of a program to study the constituents of high-potency cannabis and its pharmacological effects,<sup>2–5,7,13</sup> reported herein are the isolation and structure elucidation of eight minor cannabinoid constituents, including seven new compounds (1–7) and one known compound (8). Binding affinities of these compounds to both CB1 and CB2 receptors as well as their pharmacological evaluation in a mouse tetrad assay are described.

Received: January 22, 2015



## RESULTS AND DISCUSSION

Compound **1** was isolated as a yellow oil. Its molecular formula was determined as  $C_{21}H_{30}O_3$  from the positive-mode HRESIMS ion at  $m/z$  331.2262  $[M + H]^+$  and from the GC-MS and  $^{13}C$  NMR spectra. The  $^1H$  NMR spectrum (Table 1) of **1** displayed four methyl signals ( $\delta_H$  0.87, 1.09, 1.42, and 1.80), two aromatic proton signals ( $\delta_H$  6.11 and 6.27), five methylenes, and three methines. The  $^{13}C$  NMR spectrum (Table 2) displayed 21 carbon resonances, in good agreement with  $\Delta^9$ -THC.<sup>3,27</sup> The presence of an oxymethine carbon at  $\delta_C$  68.8 corresponding to a

proton resonance at  $\delta_H$  4.10 in the HMQC spectrum indicated that **1** is a hydroxylated  $\Delta^9$ -THC derivative. The location of the hydroxy group was determined at C-8 based on the HMBC correlations of H-8 ( $\delta_H$  4.10) with C-6a ( $\delta_C$  40.8), C-11 ( $\delta_C$  20.8), and C-10 ( $\delta_C$  128.6) (Figure 1). The  $\alpha$ -orientation of the hydroxy group at C-8 was assigned from the ROESY correlation of H-8 with H-6a ( $\delta_H$  1.81) (Figure 1). On the basis of these experiments, the chemical structure of **1** was elucidated as 8 $\alpha$ -hydroxy- $\Delta^9$ -tetrahydrocannabinol.

Compound **2** was found to possess the same molecular formula as **1**,  $C_{21}H_{30}O_3$ , and was obtained as a yellow oil. The  $^1H$  and  $^{13}C$  NMR data of **2** (Tables 1 and 2) were quite similar to those of **1** except for the higher frequency shifts of H-8 ( $\delta_H$  4.31) and C-8 ( $\delta_C$  72.4), indicating the  $\beta$ -orientation of the hydroxy group at C-8, which was confirmed by the ROESY correlation of H-8 and H-10<sub>a</sub> (Figure 1). Thus, the structure of **2** was established as 8 $\beta$ -hydroxy- $\Delta^9$ -tetrahydrocannabinol.

Compound **3** was isolated as a yellow oil. The molecular formula was established as  $C_{21}H_{30}O_3$  based on the  $[M + H]^+$  ion peak at  $m/z$  331.2266. The  $^1H$  and  $^{13}C$  NMR spectroscopic data of **3** (Tables 1 and 2) were similar to those reported for  $\Delta^8$ -THC<sup>28</sup> but with an extra hydroxy group ( $\delta_H$  4.27,  $\delta_C$  77.5). The location of this hydroxy group was determined at C-10 based on the COSY correlation between H-10 ( $\delta_H$  4.27) and H-10<sub>a</sub> ( $\delta_H$  2.77), and this was confirmed by HMBC (H-10/C-6a, C-11, C-8; H-8/C-10; H<sub>3</sub>-11/C-10; H-6a/C-10) correlations (Figure 1). The configuration at C-10 was determined by a ROESY correlation between H-10 ( $\delta_H$  4.27) and H-6a ( $\delta_H$  1.85), which supported the structural assignment of **3** as 10 $\alpha$ -hydroxy- $\Delta^8$ -tetrahydrocannabinol.


Compound **4** was obtained as a yellow oil. Its NMR spectroscopic data (Tables 1 and 2) were quite similar to those of **3** except for the downfield shift of H-10 ( $\delta_H$  5.08) and the upfield shift of C-10 ( $\delta_C$  68.3). The upfield shift of C-10 was due to the *syn* relationship with the aryl moiety at C-10<sub>a</sub>, which indicated the  $\beta$ -orientation of the hydroxy group at C-10. This was confirmed by a small coupling constant (2.4 Hz) between H-10 and H-10<sub>a</sub> and ROESY correlations between H-10 and H-10<sub>a</sub>. The structure of **4** was thus established as 10 $\beta$ -hydroxy- $\Delta^8$ -tetrahydrocannabinol.

Table 1.  $^1H$  NMR Spectroscopic Data for Compounds 1–7 in  $CDCl_3$ .

	1	2	3	4	5	6	7
position	$\delta_H$ (J in Hz)	$\delta_H$ (J in Hz)	$\delta_H$ (J in Hz)	$\delta_H$ (J in Hz)	$\delta_H$ (J in Hz)	$\delta_H$ (J in Hz)	$\delta_H$ (J in Hz)
2	6.11, s	6.15, s	6.12, s	6.12, s	6.23, s	6.25, s	
4	6.27, s	6.24, s	6.30, s	6.27, s	6.15, s	6.25, s	6.25, s
6a	1.81, m	1.80, m	1.85, m	1.85, m	1.75, dt (10.6, 3.6)	1.85, m	1.62, m
7	2.41, m	2.41, m	2.10, m	2.38, m	1.86, m	1.56, m	1.94, m 1.35, m
8	4.10, d (4.8)	4.31, bt	5.68, d (5.6)	5.62, bs	2.21, m	1.82, m	2.26, m
10	6.66, bs	6.54, bs	4.27, d (8.4)	5.08, d (2.4)	4.22, d (8.8)	3.88, bs	6.79, s
10a	3.11, d (11.2)	3.30, d (10)	2.77, t (8.1)	2.70, m	2.69, t (10.2)	2.79, d (12.0)	3.27, m
11	1.80, s	1.76, s	1.76, s	1.84, s	5.10, bs	1.36, s	4.48, s
					4.94, bs		
12	1.42, s	1.39, s	1.37, s	1.40, s	1.35, s	1.39, s	1.45, s
13	1.09, s	1.09, s	1.04, s	1.11, s	1.01, s	1.03, s	1.11, s
1'	2.41, dd (6.4, 8.4)	2.41, dd (6, 8.4)	2.42, m	2.40, m	2.43, dd (8.4, 6.0)	2.44, m	2.93, m
2'	1.55, m	1.54, m	1.55, m	1.55, m	1.56, m	1.54, m	1.58, m
3'	1.29, m	1.29, m	1.29, m	1.29, m	1.30, m	1.31, m	1.23, m
4'	1.29, m	1.29, m	1.29, m	1.29, m	1.30, m	1.31, m	1.23, m
5'	0.87, t (6.8)	0.87, t (7.1)	0.89, t (6.8)	0.89, t (6.8)	0.87, t (6.4)	0.88, t (6.8)	0.89, t (6.9)
OCOCH <sub>3</sub>							2.07, s

Table 2.  $^{13}\text{C}$  NMR Spectroscopic Data for Compounds 1–8 in  $\text{CDCl}_3$ 

position	1	2	3	4	5	6	7	8
1	155.1	154.9	156.2	154.8	156.4	155.0	164.7	156.9
2	107.9	107.9	109.9	107.8	110.3	107.9	102.7	108.5
3	143.3	143.2	144.0	143.6	144.1	143.7	147.5	143.4
4	110.4	110.1	110.1	110.5	110.1	109.3	112.8	110.3
5	154.4	154.5	155.1	156.7	155.1	155.0	159.8	154.9
6	77.0	76.7	75.3	76.6	76.2	77.3	78.9	77.1
6a	40.8	46.1	45.0	37.4	46.0	44.5	45.3	39.7
7	35.7	36.2	28.1	28.2	27.3	22.9	24.6	23.3
8	68.8	72.4	125.6	124.0	30.7	31.1	29.9	33.9
9	134.6	135.7	135.1	135.3	148.8	59.9	132.5	77.1
10	128.6	128.4	77.5	68.3	79.1	65.4	129.5	73.1
10a	34.7	34.4	41.0	38.5	41.7	36.4	33.7	36.4
10b	107.8	108.4	108.9	106.5	109.1	107.2	109.0	107.0
11	20.8	19.7	19.5	21.8	110.4	24.2	68.9	28.0
12	27.7	27.6	27.9	27.8	28.0	27.9	27.6	28.6
13	19.9	19.6	18.7	19.2	18.8	19.2	19.7	19.1
1'	35.7	35.7	35.6	35.6	35.6	35.9	35.6	35.7
2'	30.9	30.9	30.7	30.7	30.4	30.9	30.4	30.8
3'	31.7	31.7	31.8	31.9	31.8	31.8	31.8	31.9
4'	22.7	22.7	22.8	22.8	22.8	22.7	22.8	22.8
5'	14.3	14.3	14.3	14.3	14.3	14.3	14.3	14.2
OCOCH <sub>3</sub>							21.3	
OCOCH <sub>3</sub>							171.5	
COOH							176.5	

Figure 1. Key HMBC ( $\rightarrow$ ) and ROESY ( $\leftrightarrow$ ) correlations compounds 1–3 and 5–7.

Compound **5** was obtained as a yellow resin with a molecular formula of  $\text{C}_{21}\text{H}_{30}\text{O}_3$ , as indicated by the HRESIMS ( $m/z$  331.2266,  $[\text{M} + \text{H}]^+$ ). The 1D NMR data were found to be closely similar to those of **3**, with the only difference being the presence of signals for an exocyclic methylene ( $\delta_{\text{H}}$  4.94, 5.10, 1H each, s;  $\delta_{\text{C}}$  110.4, 148.8) instead of a double bond between C-8 and C-9 (Tables 1 and 2). This was supported by the HMBC correlations between H<sub>2</sub>-11 ( $\delta_{\text{H}}$  4.94, 5.10) and C-9 ( $\delta_{\text{C}}$  148.8), C-10 ( $\delta_{\text{H}}$  79.1), and C-8 ( $\delta_{\text{H}}$  30.7). The NOESY correlations between H-10 ( $\delta_{\text{H}}$  4.22) and H-6a ( $\delta_{\text{H}}$  1.74) (Figure 1) indicated the  $\alpha$ -orientation of the hydroxy group at C-10. Hence, the structure of compound **5** was determined as 10 $\alpha$ -hydroxy- $\Delta^9$ ,11-hexahydrocannabinol.

Compound **6** was isolated as a yellow oil. The molecular formula was determined as  $\text{C}_{21}\text{H}_{30}\text{O}_3$  from its HRESIMS  $[\text{M} + \text{H}]^+$  ion at  $m/z$  331.2256, indicating seven degrees of unsaturation. The  $^1\text{H}$ ,  $^{13}\text{C}$ , DEPT, and HMQC NMR spectroscopic data displayed four methyls, six methylenes, and five methines (Tables 1 and 2). The spectroscopic data were similar to those of  $\Delta^9$ -THC,<sup>3,27</sup> except for the epoxidation of the olefinic group at C-9 and C-10 [ $\delta_{\text{H}}$  3.88 (H-10, s),  $\delta_{\text{C}}$  65.4 (C-10)

and  $\delta_{\text{C}}$  59.9 (C-9)]. The ROESY correlation between H-10 ( $\delta_{\text{H}}$  3.88) and H-10a ( $\delta_{\text{H}}$  2.78) was used to determine the orientation of the epoxy moiety as  $\beta$  (Figure 1). Therefore, compound **6** was identified as 9 $\beta$ ,10 $\beta$ -epoxyhexahydrocannabinol.

Compound **7** was isolated as a brown oil. Its HRESIMS exhibited a sodiated molecular ion peak at  $m/z$  439.2092  $[\text{M} + \text{Na}]^+$ , corresponding to the molecular formula  $\text{C}_{24}\text{H}_{32}\text{O}_6\text{Na}$  (calcd  $m/z$  439.2097). Thus, **7** was assigned with eight degrees of unsaturation. Its IR spectrum showed strong absorptions at  $\nu_{\text{max}}$  1734 and 1644  $\text{cm}^{-1}$ , indicative of ester and hydrogen-bonded carbonyl groups, respectively. The spectroscopic data of **7** were similar to those of  $\Delta^9$ -tetrahydrocannabinolic acid A,<sup>3,27</sup> with the absence of the CH<sub>3</sub>-11 signals and the presence of an acetoxy methyl moiety instead [ $\delta_{\text{H}}$  2.07 (H<sub>3</sub>, s), 4.48 (H<sub>2</sub>, s);  $\delta_{\text{C}}$  21.3, 68.9, and 176.5]. The  $J_3$ -HMBC correlation between H-10 ( $\delta_{\text{H}}$  6.79) and the oxymethylene carbon at  $\delta_{\text{C}}$  68.9 as well as that between oxymethylene protons ( $\delta_{\text{H}}$  4.48, H<sub>2</sub>-11) and C-10 ( $\delta_{\text{C}}$  129.5) (Figure 1) was used to place the acetoxy group at C-11. The structure of **7** was assigned as 11-acetoxy- $\Delta^9$ -tetrahydrocannabinolic acid A.

Compound **8** was identified as cannabiripsol by comparing its specific rotation, GC-MS, and  $^1\text{H}$  NMR data with literature values,<sup>28</sup> but this is the first time its  $^{13}\text{C}$  NMR spectroscopic data (Table 2) have been reported.

Compounds **1**, **2**, and **6** were previously reported as metabolites of  $\Delta^9$ -THC, and they have been synthesized, but their identification was established by GC and  $^1\text{H}$  NMR spectroscopy only.<sup>29–31</sup> Compounds **3** and **5** were synthesized by Pitt et al. in 1975, but their chemical structures were determined only by  $^1\text{H}$  NMR spectroscopy.<sup>32</sup> This is the first time that compounds **1–3** and **5** and **6** have been isolated from a natural source and have had their full spectroscopic data reported.

Cell lines were established expressing either the full-length human cannabinoid-1 receptor or the full-length human

cannabinoid-2 receptor. Radioligand binding assays were performed to assess the affinity of these hydroxylated cannabinoid compounds.<sup>33</sup> Most of the tested compounds exhibited a submicromolar affinity toward the receptors and, in some cases, demonstrated a several-fold selectivity toward the CB-1 receptor. Of these, 10- $\alpha$ -hydroxy- $\Delta^8$ -tetrahydrocannabinol (3) was found to bind to both the cannabinoid receptors nearly as tightly as THC and is a partial agonist at both receptors (Table 3).

**Table 3. Binding Affinities of Compounds 1–8,  $\Delta^9$ -THC, and  $\Delta^8$ -THC**

compound	binding affinity (nM)	
	CB1	CB2
1	1906 $\pm$ 578	3219 $\pm$ 876
2	65 $\pm$ 16	88 $\pm$ 19
3	31 $\pm$ 6	30 $\pm$ 4
4	830 $\pm$ 94	3274 $\pm$ 515
5	117 $\pm$ 16	129 $\pm$ 13
6	224 $\pm$ 20	335 $\pm$ 36
7	47 $\pm$ 18	912 $\pm$ 77
8	5668 $\pm$ 1324	2143 $\pm$ 353
$\Delta^8$ -THC	78 $\pm$ 5	12 $\pm$ 2
$\Delta^9$ -THC	18 $\pm$ 4	42 $\pm$ 9

The mouse tetrad assay is a four-point behavioral assay that characterizes the effect on locomotor activity, catalepsy, body temperature, and nociception. The neurobehavioral effects of  $\Delta^9$ -THC in the mouse tetrad assay are well established and are

typically referred to as classical cannabimimetic action. These activities manifest as a reduction in locomotor activity, catalepsy, hypothermia, and antinociceptive effects.<sup>34–36</sup> The results shown in Table 4 indicate that compounds 3 and 6 showed the most potent cannabimimetic-like actions in this mouse tetrad assay. Both compounds exerted significant hypolocomotive, cataleptic, and hypothermic as well as antinociceptive effects in both the tail-flick and hot-plate assays. On the other hand, compound 2 lacked typical cannabimimetic-like action at doses up to 20 mg/kg, but exhibited a significant dose-dependent hypolocomotive activity. Interestingly, compound 4 administration resulted in hypothermic and antinociceptive activity at 40 mg/kg, while a significant locomotor stimulant effect was produced at a 10 mg/kg dose.

The data collected from the in vivo tetrad activity assay (Table 4) correlated with the order of in vitro binding affinities of the isolated compounds with the CB1 receptors (Table 3). Thus, compound 3 showed typical cannabimimetic actions in vivo and possessed the highest binding affinities to the CB1 and CB2 receptors, with  $K_i$  values of 31.0  $\pm$  6.0 and 30.0  $\pm$  4.0 nM, respectively.<sup>33</sup> Additionally, compound 3 proved to act as a partial CB1 agonist in functional assays, similar to the classical cannabinoid,  $\Delta^9$ -THC. In contrast, compound 2 lacked any cannabimimetic activity at the doses tested and showed poor binding affinity to the CB1 receptors. On the other hand, compound 4 showed a partial cannabimimetic action and at the highest tested dose (40 mg/kg) exerted only antinociceptive and hypothermic actions. While compound 1 showed a binding affinity to the CB1 ( $K_i$  = 1.91  $\pm$  0.58  $\mu$ M) receptor, it did not exhibit typical cannabimimetic activity in the mouse tetrad assay

**Table 4. Behavioral Effects of the Intraperitoneal Administration of Selected Cannabinoids in a Mouse Tetrad Assay**

treatment group (mg/kg)	locomotor activity	catalepsy latency (s)	tail-flick latency (% MPE)	hot-plate latency (% MPE)	decrease in rectal temperature ( $^{\circ}$ C)
vehicle	2091 $\pm$ 209.3	2.1 $\pm$ 0.60	0.84 $\pm$ 3.58	8.32 $\pm$ 2.20	0.58 $\pm$ 0.26
$\Delta^9$ -THC					
10	190.9 $\pm$ 33.8 <sup>c</sup>	14.4 $\pm$ 4.16	6.52 $\pm$ 2.00	29.04 $\pm$ 5.37 <sup>c</sup>	2.05 $\pm$ 0.25
20	276.2 $\pm$ 52.6 <sup>c</sup>	47.9 $\pm$ 20.04 <sup>b</sup>	42.21 $\pm$ 17.04 <sup>b</sup>	46.85 $\pm$ 9.08 <sup>c</sup>	4.25 $\pm$ 0.78 <sup>c</sup>
40	194.0 $\pm$ 49.2 <sup>c</sup>	37.7 $\pm$ 14.64 <sup>a</sup>	51.96 $\pm$ 13.22 <sup>c</sup>	38.18 $\pm$ 4.05 <sup>c</sup>	4.80 $\pm$ 0.28 <sup>c</sup>
$\Delta^8$ -THC					
5	1480 $\pm$ 184.3	1.6 $\pm$ 0.60	8.01 $\pm$ 5.88	12.82 $\pm$ 1.84	0.12 $\pm$ 0.09
20	377.4 $\pm$ 169.7 <sup>c</sup>	5.3 $\pm$ 2.68	5.97 $\pm$ 1.63	16.98 $\pm$ 3.53	1.96 $\pm$ 0.37 <sup>a</sup>
compound 1					
20	908.90 $\pm$ 245.10	1.50 $\pm$ 0.33	5.01 $\pm$ 3.59	4.95 $\pm$ 1.89	0.58 $\pm$ 0.18
compound 2					
10	1617 $\pm$ 364.50	1.143 $\pm$ 0.14	0.13 $\pm$ 3.50	11.83 $\pm$ 3.16	0.49 $\pm$ 0.49
20	1148 $\pm$ 242.60 <sup>a</sup>	1.43 $\pm$ 0.29	1.62 $\pm$ 3.92	2.04 $\pm$ 2.48	0.50 $\pm$ 0.31
40	777.40 $\pm$ 185.10 <sup>b</sup>	11.43 $\pm$ 3.92	12.69 $\pm$ 6.62	11.79 $\pm$ 2.48	0.91 $\pm$ 0.18
compound 3					
5	318.1 $\pm$ 96.29 <sup>c</sup>	22.0 $\pm$ 12	37.40 $\pm$ 12.62 <sup>a</sup>	21.04 $\pm$ 6.27	2.46 $\pm$ 0.52 <sup>b</sup>
10	288.3 $\pm$ 98.7 <sup>c</sup>	23.9 $\pm$ 6.71	31.46 $\pm$ 12.64	56.33 $\pm$ 8.61 <sup>c</sup>	3.21 $\pm$ 0.3 <sup>c</sup>
20	301.9 $\pm$ 62.9 <sup>c</sup>	51.1 $\pm$ 18.59 <sup>a</sup>	90.16 $\pm$ 6.16 <sup>c</sup>	47.63 $\pm$ 7.80 <sup>c</sup>	5.38 $\pm$ 0.38 <sup>c</sup>
compound 4					
10	3045 $\pm$ 266.3 <sup>a</sup>	1.4 $\pm$ 0.31	2.20 $\pm$ 1.16	6.819 $\pm$ 3.18	0.47 $\pm$ 0.18
40	2537 $\pm$ 316.1	13.70 $\pm$ 4.55	69.95 $\pm$ 14.02 <sup>c</sup>	55.65 $\pm$ 7.74 <sup>c</sup>	5.32 $\pm$ 0.29 <sup>c</sup>
compound 6					
5	213.40 $\pm$ 49.77 <sup>c</sup>	23.80 $\pm$ 10.55 <sup>a</sup>	16.25 $\pm$ 7.08	36.98 $\pm$ 8.87 <sup>a</sup>	3.75 $\pm$ 0.42 <sup>c</sup>
10	291.20 $\pm$ 69.89 <sup>c</sup>	8.80 $\pm$ 3.39	82.71 $\pm$ 11.31 <sup>c</sup>	35.89 $\pm$ 7.56 <sup>a</sup>	3.11 $\pm$ 0.25 <sup>c</sup>
20	380.30 $\pm$ 109.70 <sup>c</sup>	27.50 $\pm$ 7.83 <sup>a</sup>	50.37 $\pm$ 15.99 <sup>b</sup>	49.39 $\pm$ 13.81 <sup>b</sup>	4.58 $\pm$ 0.65 <sup>c</sup>
compound 8					
20	1892 $\pm$ 121.20	2.25 $\pm$ 1.25	2.98 $\pm$ 2.36	2.40 $\pm$ 6.71	0.45 $\pm$ 0.20

<sup>a</sup> $p$  < 0.05. <sup>b</sup> $p$  < 0.01. <sup>c</sup> $p$  < 0.001 versus vehicle (Dunnett's posthoc test).



at a dose of 20 mg/kg. Additional quantities of this compound need to be secured by isolation or synthetic techniques in order to further evaluate its functional activity at the CB1 receptor as well as to characterize its full in vivo dose–response activity. It is crucial to determine if compound **1** acts as an agonist or antagonist of CB1. An antagonist effect would result in the lack of cannabimimetic activity in the tetrad assay, while an antagonist effect would block an agonist effect (e.g.,  $\Delta^9$ -THC) in this four-point behavioral assay. In addition, a full receptor binding panel evaluation should be conducted to determine if compound **1** interacts with other CNS receptors that might mask the cannabimimetic activity inferred by CB1 binding. Future binding studies of the isolated compounds to targets other than the CB1 and CB2 receptors, like the transient receptor potential (TRP) channels of both the vanilloid type-3 (TRPV3) and the ankyrin type-1 (TRPA1), are needed to better establish the mechanism and potential value of the pharmacological effects observed in this study.

## EXPERIMENTAL SECTION

**General Experimental Procedures.** Optical rotations were measured on an Autoplot IV automatic polarimeter. IR spectra were recorded on a Bruker Tensor 27 IR spectrometer.  $^1\text{H}$  NMR (400 MHz),  $^{13}\text{C}$  NMR (100 MHz), DEPT-135, APT, and 2D NMR spectra were recorded using the residual solvent signal as an internal standard on a Varian AS 400 NMR spectrometer. High-resolution mass spectra were measured using a Bruker BioApex instrument. HPLC was performed on a Waters Delta Prep 4000 preparative chromatography system connected to a Waters 486 tunable UV absorbance detector using Phenomenex Luna C<sub>18</sub> and Si gel columns (250 × 21.2 mm, 5  $\mu\text{m}$ , 100 Å). GC-MS analysis was carried out on an HP 6890 series GC, equipped with a split/splitless capillary injector, an HP 6890 series injector autosampler, and an Agilent DB-5 ms column (30 m × 0.25 mm × 0.25  $\mu\text{m}$ ), interfaced to an HP 5973 mass selective detector. The injector temperature was 250 °C, and 1  $\mu\text{L}$  injections were performed in the splitless mode, with the splitless time set at 60 s, the split flow set at 50 mL/min, and the septum purge valve set to close 60 s after the injection occurred. The oven temperature was raised from 70 to 270 °C (held for 20 min) at a rate of 5 °C/min, for a total run time of 60 min; the transfer line temperature was 280 °C. Chemicals and reagents for pharmacological studies were obtained from Sigma-Aldrich (St. Louis, MO, USA) except fetal bovine serum (Midwest Scientific, Valley Park, MO, USA) and Biorad Bradford dye (Fisher Scientific, Pittsburgh, PA, USA).

**Plant Material.** *Cannabis sativa* plants were grown from high-potency Mexican seeds at The University of Mississippi growing field (University, MS, USA) and were harvested in December 2007. The plants were authenticated by Dr. Suman Chandra at The University of Mississippi, and a voucher specimen (S1310 V1) has been deposited at the Coy Waller Complex, National Center for Natural Products Research, School of Pharmacy, The University of Mississippi.

**Extraction and Isolation.** The dried plant material (9.0 kg) was extracted sequentially with hexanes (48 L),  $\text{CH}_2\text{Cl}_2$  (40 L), EtOAc (40 L), EtOH (40 L), EtOH–H<sub>2</sub>O (36 L, 1:1), and H<sub>2</sub>O (40 L) at room temperature. The extracts were evaporated under reduced pressure at 40 °C to afford hexanes (1.48 kg),  $\text{CH}_2\text{Cl}_2$  (0.15 kg), EtOAc (0.13 kg), EtOH (0.09 kg), EtOH–H<sub>2</sub>O (0.77 kg), and H<sub>2</sub>O (0.54 kg) extracts, for a total extract weight of 3.16 kg (35.1%, w/w). Portions of the  $\text{CH}_2\text{Cl}_2$ , EtOAc, and EtOH extracts were combined (191.0 g) since they showed similar TLC profiles (EtOAc–*n*-hexane, 4:6) and were subjected to silica gel VLC, eluting with EtOAc–*n*-hexane [0:100, 10:90, 20:80, 30:70, 40:60, 50:50, 75:25, 100:0 (2 L of each mixture)] followed by EtOH (4 L), yielding nine pooled fractions (A–I). Fraction D (14.3 g) was fractionated on a Si gel column using EtOAc–petroleum ether (5:95 to 50:50) for elution to afford four fractions (D<sub>1</sub>–D<sub>4</sub>). Fraction D<sub>2</sub> (2 g) was subjected to passage over a C<sub>18</sub> flash column (MeOH–H<sub>2</sub>O, 6:4), followed by a C<sub>18</sub>-SPE column, and was finally purified by Si gel HPLC (EtOAc–*n*-hexane, 10:90) to give **3** (14.0 mg,  $t_{\text{R}}$  15.0 min), **4**

(25.0 mg,  $t_{\text{R}}$  12.3 min), and **5** (11.9 mg,  $t_{\text{R}}$  11.3 min). Compound **7** (9.8 mg) was isolated from fraction D<sub>3</sub> (626 mg) by repeated C<sub>18</sub> flash column chromatography (MeCN–H<sub>2</sub>O, 70–100%), passage over Sephadex LH-20 (MeOH), and Si gel solid-phase extraction (MeOH– $\text{CH}_2\text{Cl}_2$ , 0–10%). Fraction G (6.95 g) was subjected to Si gel column chromatography using a stepwise gradient system using mixtures of EtOAc–*n*-hexane (0:100 to 100:0), giving 13 fractions (G<sub>1</sub>–G<sub>13</sub>). Fraction G<sub>11</sub> (2.78 g) was further purified by passage over Sephadex LH-20 eluted with MeOH, followed by reversed-phase HPLC (MeOH–H<sub>2</sub>O, 75:25), to give **1** (15.7 mg,  $t_{\text{R}}$  11.4 min), **2** (24.6 mg,  $t_{\text{R}}$  12.9 min), **6** (21.2 mg,  $t_{\text{R}}$  13.2 min), and **8** (35.5 mg,  $t_{\text{R}}$  9.1 min).

**8 $\alpha$ -Hydroxy- $\Delta^9$ -tetrahydrocannabinol (1):** yellow oil;  $[\alpha]_{\text{D}}^{25}$  –56.6 (c 0.21,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR, see Tables 1 and 2; HRESIMS  $m/z$  331.2262  $[\text{M} + \text{H}]^+$  (calcd for C<sub>21</sub>H<sub>31</sub>O<sub>3</sub>, 331.2273); GC-MS  $m/z$  330 ( $\text{M}^+$ , 35%), 315 (16%), 297 (16%), 271 (100%).

**8 $\beta$ -Hydroxy- $\Delta^9$ -tetrahydrocannabinol (2):** yellow oil;  $[\alpha]_{\text{D}}^{25}$  –122.8 (c 0.17,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR, see Tables 1 and 2; HRESIMS  $m/z$  331.2274  $[\text{M} + \text{H}]^+$  (calcd for C<sub>21</sub>H<sub>31</sub>O<sub>3</sub>, 331.2273); GC-MS  $m/z$  330 ( $\text{M}^+$ , 35%), 315 (51%), 312 (98%), 297 (89%), 271 (100%), 214 (42%).

**10 $\alpha$ -Hydroxy- $\Delta^8$ -tetrahydrocannabinol (3):** yellow oil;  $[\alpha]_{\text{D}}^{25}$  –29.6 (c 0.34,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR, see Tables 1 and 2; HRESIMS  $m/z$  331.2266  $[\text{M} + \text{H}]^+$  (calcd for C<sub>21</sub>H<sub>31</sub>O<sub>3</sub>, 331.2273); GC-MS  $m/z$  330 ( $\text{M}^+$ , 20%), 312 (85%), 297 (100%), 257 (26%), 231 (70%), 214 (55%).

**10 $\beta$ -Hydroxy- $\Delta^8$ -tetrahydrocannabinol (4):** yellow oil;  $[\alpha]_{\text{D}}^{25}$  –78.7 (c 0.59,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR, see Tables 1 and 2; HRESIMS  $m/z$  331.2268  $[\text{M} + \text{H}]^+$  (calcd for C<sub>21</sub>H<sub>31</sub>O<sub>3</sub>, 331.2273); GCMS  $m/z$  330 ( $\text{M}^+$ , 8%), 312 (100%), 297 (98%), 269 (16%), 257 (30%), 231 (68%), 214 (75%).

**10 $\alpha$ -Hydroxy- $\Delta^{9,11}$ -hexahydrocannabinol (5):** yellow oil;  $[\alpha]_{\text{D}}^{25}$  –99.1 (c 0.43,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR, see Tables 1 and 2; HRESIMS  $m/z$  331.2266  $[\text{M} + \text{H}]^+$  (calcd for C<sub>21</sub>H<sub>31</sub>O<sub>3</sub>, 331.2273).

**9 $\beta$ ,10 $\beta$ -Epoxyhexahydrocannabinol (6):** yellow oil;  $[\alpha]_{\text{D}}^{25}$  –36.6 (c 0.06,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR, see Tables 1 and 2; HRESIMS  $m/z$  331.2256  $[\text{M} + \text{H}]^+$  (calcd for C<sub>21</sub>H<sub>31</sub>O<sub>3</sub>, 331.2273); GC-MS  $m/z$  330 ( $\text{M}^+$ , 28%), 315 (50%), 297 (24%), 271 (100%), 231 (25%), 193 (10%).

**11-Acetoxy- $\Delta^9$ -tetrahydrocannabinolic acid A (7):** brown oil;  $[\alpha]_{\text{D}}^{25}$  –150.0 (c 0.51,  $\text{CHCl}_3$ ); IR (neat)  $\nu_{\text{max}}$  2927, 1734, 1644, 1615, 1565, 1466  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR, see Tables 1 and 2; HRESIMS  $m/z$  439.2092  $[\text{M} + \text{Na}]^+$  (calcd for C<sub>23</sub>H<sub>32</sub>O<sub>6</sub>Na, 439.2097).

**Cannabiripsol (8):** white powder;  $[\alpha]_{\text{D}}^{25}$  129 (c 0.09,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR, consistent with literature values;<sup>28</sup>  $^{13}\text{C}$  NMR data, see Table 2; HRESIMS  $m/z$  349.2393  $[\text{M} + \text{H}]^+$  (calcd for C<sub>21</sub>H<sub>33</sub>O<sub>4</sub>, 349.2379).

**CB1 and CB2 Receptor Radioligand Binding Assays.** The CB1 and CB2 receptor radioligand binding assays of the isolated compounds were performed according to a previously reported method.<sup>33</sup>

**Animals.** Experiments were performed using 8-week-old mice. Male Swiss Webster mice (Harlan, Indianapolis, IN, USA), weighing 24–30 g at the time of testing, were used. The mice were housed in groups of five with a 12 h light/12 h dark cycle. Food and water were provided ad libitum. All mice were selected randomly for each treatment group. Procedures involving animals were performed according to the guidelines approved by the Institutional Animal Care and Use Committee (IACUC) at The University of Mississippi and according to the National Institutes of Health Guide Care and Use of Laboratory Animals (IACUC number 07-018).

**Mouse Tetrad Assay.** Twenty-four hours prior to testing, animals were acclimated to the experimental setting (ambient temperature, 22–24 °C, hot-plate chamber, and rectal probe insertion). On the day of testing, preinjection control values for rectal temperature, catalepsy, tail-flick, and hot-plate latencies were determined. Animals were then injected intraperitoneally (ip) with either the vehicle control,  $\Delta^9$ -THC (10–40 mg/kg), or test compound (5–40 mg/kg). Following ip injection, animals were placed individually in activity chambers (San Diego Instruments, San Diego, CA, USA), where the locomotor activity was monitored automatically for 30 min. Total activity was expressed as the total number of interruptions of 16-cell photobeams per chamber.

The activity for the last 10 min was recorded for analysis. Animals were then placed on a ring immobility apparatus, and the latency to drop was recorded in seconds with a maximum cutoff of 180 s latency. Rectal temperature was recorded using a digital rectal probe (Physitemp Instruments, Clifton, NJ, USA) and was expressed as the difference between basal and postinjection temperatures. Tail-flick and hot-plate latencies were measured with a maximum tail-flick latency of 15 s and hot-plate latency of 45 s to avoid tissue damage.

**Data Analysis.** All values were presented as means  $\pm$  SEM with  $n = 6-8$  animals per group. Antinociception was expressed as the percent maximal effect (% MPE = [(post drug latency – basal latency)/(cutoff latency – basal)]  $\times$  100). All data were analyzed using one-way ANOVA followed by a Dunnett's post hoc test to determine significant differences from the vehicle control at  $p < 0.05$ .

## ■ ASSOCIATED CONTENT

### ● Supporting Information

$^1\text{H}$  NMR,  $^{13}\text{C}$  NMR, and DEPT-135 spectra for the isolated compounds (1–8). The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jnatprod.5b00065.

## ■ AUTHOR INFORMATION

### Corresponding Authors

\*Tel: 1-662-915-5928. Fax: +1-662-915-5587. E-mail: melsohly@olemiss.edu (M. A. ElSohly).

\*Tel: +1-662-915-1031. Fax: +1-662-915-7989. E-mail: sross@olemiss.edu (S. A. Ross).

### Present Addresses

<sup>†</sup>Pharmaceutical Sciences Department, College of Pharmacy, Chicago State University, Chicago, Illinois 60628-1598, United States.

<sup>‡</sup>Department of Pharmacognosy, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt.

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

This project was supported by grant no. SP20RR021929-02 from the National Center for Research Resources and in part by the National Institute on Drug Abuse, contract no. N01DA-5-7746. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. We thank Dr. G. Ma for help with the CHO transfection experiments.

## ■ REFERENCES

- (1) ElSohly, M. A.; Slade, D. *Life Sci.* **2005**, *78*, 539–548.
- (2) Ahmed, S. A.; Ross, S. A.; Slade, D.; Radwan, M. M.; Khan, I. A.; ElSohly, M. A. *Tetrahedron Lett.* **2008**, *49*, 6050–6053.
- (3) Ahmed, S. A.; Ross, S. A.; Slade, D.; Radwan, M. M.; Zulfikar, F.; ElSohly, M. A. *J. Nat. Prod.* **2008**, *71*, 536–542.
- (4) Radwan, M. M.; ElSohly, M. A.; Slade, D.; Ahmed, S. A.; Wilson, L.; El-Alfy, A. T.; Khan, I. A.; Ross, S. A. *Phytochemistry* **2008**, *69*, 2627–2633.
- (5) Radwan, M. M.; Ross, S. A.; Slade, D.; Ahmed, S. A.; Zulfikar, F.; ElSohly, M. A. *Planta Med.* **2008**, *74*, 267–272.
- (6) Appendino, G.; Giana, A.; Gibbons, S.; Maffei, M.; Gnani, G.; Grassi, G.; Sterner, O. *Nat. Prod. Commun.* **2008**, *12*, 1977–1980.
- (7) Radwan, M. M.; ElSohly, M. A.; Slade, D.; Ahmed, S. A.; Khan, I. A.; Ross, S. A. *J. Nat. Prod.* **2009**, *72*, 906–911.
- (8) Qian, S.; Cai, G.; He, G.; Du, F. L. *Nat. Prod. Res. Dev.* **2009**, *21*, 784–786.
- (9) Cheng, L.; Kong, D.; Hu, G.; Li, H. *Chem. Nat. Compd.* **2010**, *46*, 710–712.
- (10) Taglialatela-Scafati, O.; Pagani, A.; Scala, F.; De Petrocellis, L.; Di Marzo, V.; Grassi, G.; Giovanni, G.; Appendino, G. *Eur. J. Org. Chem.* **2010**, *11*, 2067–2072.
- (11) Pagani, A.; Scala, F.; Chianese, G.; Grassi, G.; Appendino, G.; Taglialatela-Scafati, O. *Tetrahedron* **2011**, *67*, 3369–3373.
- (12) Pollastro, F.; Taglialatela-Scafati, O.; Allarà, M.; Munoz, E.; Di Mazo, V.; De Petrocellis, L.; Appendino, G. *J. Nat. Prod.* **2011**, *74*, 2019–2022.
- (13) Zulfikar, F.; Ross, S. A.; Slade, D.; Ahmed, S. A.; Radwan, M. M.; Zulfikar, A.; Khan, I. A.; ElSohly, M. A. *Tetrahedron Lett.* **2012**, *53*, 3560–3562.
- (14) ElSohly, M. A.; Gul, W. In *Handbook of Cannabis*; Pertwee, R. G., Ed.; Oxford University Press: Oxford, UK, 2014; Chapter 1, pp 3–22.
- (15) Gaoni, Y.; Mechoulam, R. *J. Am. Chem. Soc.* **1964**, *86*, 1646–1647.
- (16) Roberts, J. D.; Gennings, C.; Shih, M. *Eur. J. Pharmacol.* **2006**, *530*, 54–58.
- (17) Darmani, N. A.; Johnson, J. C. *Eur. J. Pharmacol.* **2004**, *488*, 201–212.
- (18) Sofia, R. D.; Kubena, R. K.; Barry, H. *Psychopharmacologia* **1973**, *31*, 121–130.
- (19) Mannila, J.; Jaervinen, T.; Jaervinen, K.; Tervonen, J.; Jarho, P. *Life Sci.* **2006**, *78*, 1911–1914.
- (20) Plange, N.; Arend, K. O.; Kaup, M.; Doehmen, B.; Adams, H.; Hendricks, S.; Cordes, A.; Huth, J.; Sponsel, W. E.; Remky, A. *Am. J. Ophthalmol.* **2007**, *143*, 173–174.
- (21) Parker, L. A.; Kwiatkowska, M.; Mechoulam, R. *Physiol. Behav.* **2006**, *87*, 66–71.
- (22) Devane, W. A.; Dysarz, F. A.; Johnson, M. R.; Melvin, L. S.; Howlett, A. C. *Mol. Pharmacol.* **1988**, *34*, 605–613.
- (23) Munro, S.; Thomas, K. L.; Abu-Shaar, M. *Nature* **1993**, *365*, 61–65.
- (24) Barth, F. *Annu. Rep. Med. Chem.* **2005**, *40*, 103–118.
- (25) Ashton, J. C.; Giass, M. *Curr. Neuropharmacol.* **2007**, *5*, 73–80.
- (26) ElSohly, M. A.; Ross, S. A.; Mehmedic, Z.; Ararat, R.; Yi, B.; Banahan, B. F. *J. Forensic Sci.* **2002**, *45*, 24–30.
- (27) Choi, Y. H.; Hazekamp, A.; Peltenburg-Looman, A. M. G.; Frederich, M.; Erkelens, C.; Lefeber, A. W. M.; Verpoorte, R. *Phytochem. Anal.* **2004**, *15*, 345–354.
- (28) Boeren, E. G.; ElSohly, M. A.; Turner, C. E. *Experientia* **1979**, *35*, 1278–1279.
- (29) Pitt, C. G.; Hauser, F.; Hawks, R. L.; Sathe, S.; Wall, M. E. *J. Am. Chem. Soc.* **1972**, *94*, 8578–8579.
- (30) Mechoulam, R.; Varconi, H.; Ben-Zvi, Z.; Edery, H.; Grunfeld, Y. *J. Am. Chem. Soc.* **1972**, *94*, 7930–7931.
- (31) Gurny, O.; Maynard, D. E.; Pitcher, R. G.; Kierstead, R. W. *J. Am. Chem. Soc.* **1972**, *94*, 7928–7929.
- (32) Pitt, C. G.; Fowler, M. S.; Sathe, S.; Srivastava, S. C.; Williams, D. L. *J. Am. Chem. Soc.* **1975**, *97*, 3798–3802.
- (33) Husni, A. S.; McCurdy, C. R.; Radwan, M. M.; Ahmed, S. A.; Slade, D.; Ross, S. A.; ElSohly, M. A.; Cutler, S. J. *Med. Chem. Res.* **2014**, *23*, 4295–4300.
- (34) Martin, B. R.; Welch, S. P.; Abood, M. *Adv. Pharmacol.* **1994**, *25*, 341–397.
- (35) Varvel, S. A.; Bridgen, D. T.; Tao, Q.; Thomas, B. F.; Martin, B. R.; Lichtman, A. H. *J. Pharmacol. Exp. Ther.* **2005**, *314*, 329–337.
- (36) Pertwee, R. G.; Thomas, A.; Stevenson, L. A.; Ross, R. A.; Varvel, S. A.; Lichtman, A. H.; Martin, B. R.; Razdan, R. K. *Br. J. Pharmacol.* **2007**, *150*, 586–594.